TD Cowen Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)

TD Cowen analyst Joseph Thome reiterated a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS).

The analyst commented, "MRNS reported Q2 Ztalmy revenues of $8MM and cash of $65MM. Focus is on Ph. III TSC topline data in the first half of Q4. Our KOLs and mgmt see a high probability of success based on blinded discontinuation rate and Ztalmy experience. We see TSC as an ~4X opportunity vs CDD, and if successful MRNS will submit an sNDA in April 2025. Cash is an overhang, but MRNS seems funded through TSC data. Buy."

For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.

Shares of Marinus Pharmaceuticals closed at $1.18 yesterday.

You May Also Be Interested In

• Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)
• Active options: NVDA TSLA SPCX MU SMCI INTC AAPL IREN AMZN